MAIOLI, GABRIELLA
MAIOLI, GABRIELLA
Dipartimento di Scienze Cliniche e di Comunità
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
2024 E.G. Favalli, G. Maioli, R. Caporali
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
2024 C.B. Chighizola, R. Willis, G. Maioli, S. Sciascia, L. Andreoli, O. Amengual, M. Radin, M. Gerosa, T. Atsumi, G. de Jesus, L. Trespidi, D.W. Branch, R. Caporali, D. Andrade, R. Roubey, M. Petri, M.L. Bertolaccini
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
2023 E.G. Favalli, G. Cincinelli, S. Germinario, R. Di Taranto, F. Orsini, G. Maioli, M. Biggioggero, M. Ferrito, R. Caporali
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
2022 A. Favalli, E.G. Favalli, A. Gobbini, E. Zagato, M. Bombaci, G. Maioli, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notarbartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Immune response to SARS-COV-2 infection in patients with rheumatic musculoskeletal diseases: the mainstream study
2022 E.G. Favalli, A. Favalli, G. Andrea, G. Maioli, E. Zagato, M. Bombaci, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notabartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis
2022 G. Maioli, R.F. Caporali, E.G. Favalli
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
2022 E.G. Favalli, A. Gobbini, M. Bombaci, G. Maioli, M. Biggioggero, E. Pesce, A. Favalli, M. Martinovic, T. Fabbris, E. Marchisio, A. Bandiera, A. Gori, S. Abrignani, R. Grifantini, R. Caporali
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
2021 E.G. Favalli, G. Maioli, M. Biggioggero, R. Caporali
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
2021 A. Zabotti, O. De Lucia, G. Sakellariou, A. Batticciotto, G. Cincinelli, I. Giovannini, L. Idolazzi, G. Maioli, I. Tinazzi, D. Aletaha, S. De Vita, A. Marchesoni, J. Smolen, A. Iagnocco, D. Mcgonagle, R. Caporali
Baricitinib for COVID-19: a suitable treatment?
2020 E.G. Favalli, M. Biggioggero, G. Maioli, R. Caporali
Current and emerging biologics for the treatment of juvenile idiopathic arthritis
2020 R. Cimaz, G. Maioli, G. Calabrese
Lung Disease in Antiphospholipid Syndrome
2019 G. Maioli, G. Calabrese, F. Capsoni, M. Gerosa, P.L. Meroni, C.B. Chighizola